Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States and Canada; and Proquin XR for the treatment of uncomplicated urinary tract infection in the United States. The company's product candidates include DM-1796 for the treatment of postherpetic neuralgia, which has completed a Phase III clinical trial; Serada for the treatment of menopausal hot flashes, which has completed a Phase III clinical trial; DM-3458 for gastroesophageal reflux disease; and DM-1992 to treat Parkinson's disease, which has completed a Phase I clinical trial. It sells its products to wholesalers and retail pharmacies. The company has collaboration and license agreements with Solvay Pharmaceuticals, Inc.; PharmaNova, Inc.; Santarus, Inc.; Merck & Co., Inc.; Covidien, Ltd.; TEVA Pharmaceuticals USA, Inc.; King Pharmaceuticals, Inc.; Esprit Pharma, Inc.; LG Life Sciences, Ltd.; Rottapharm/Madaus S.r.l.; PharmaNova, Inc.; and Supernus Pharmaceuticals, Inc. Depomed, Inc. was founded in 1995 and is based in Menlo Park, California.